Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical Trials Insight: 700020639

Trial Profile

Clinical Trials Insight: 700020639

Phase of Trial: Phase I

Latest Information Update: 03 Nov 2010

At a glance

  • Drugs CX 157 (Primary)
  • Indications Anxiety; Depressive disorders
  • Focus Adverse reactions
  • Sponsors CeNeRx BioPharma
  • Most Recent Events

    • 03 Nov 2010 Results reported in CeNeRx BioPharma media release.
    • 07 Dec 2009 According to a CeNeRx BioPharma media release CX 157 is safe and well tolerated.
    • 16 Jan 2008 Status change from initiated to completed, from a CeNeRx Biopharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top